SWM
MTNB icon

Spire Wealth Management’s Matinas BioPharma MTNB Stock Holding History

Spire Wealth Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,223
Closed -$163K – 2744
2021
Q4 		$163K Buy
3,223
+3,163
+5,272% +$169K ﹤0.01% 1182
2021
Q3 		$4K Buy
+60
New +$2.59K ﹤0.01% 2349
2021
Q2 		– Sell
-5,263
Closed -$292K – 2826
2021
Q1 		$292K Buy
+5,263
New +$353K 0.01% 880

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Spire Wealth Management's MTNB Position: Q1 2022 in Review

Spire Wealth Management sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 3,223 shares — an estimated $163K sold.

Spire Wealth Management first reported a position in MTNB in Q1 2021 and held it in 3 quarters. The position peaked at $292K in Q1 2021. 56 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

  • Spire Wealth Management reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 3,223 Matinas BioPharma shares in Q1 2022, an estimated $163K.
  • Spire Wealth Management first reported a position in Matinas BioPharma in Q1 2021 and held it in 3 quarters.
  • Spire Wealth Management's Matinas BioPharma position peaked at $292K in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.